Natera, Inc. (NASDAQ:NTRA) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 99.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,970 shares of the medical research company's stock after selling 10,003,975 shares during the period. Calamos Advisors LLC's holdings in Natera were worth $3,636,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Wellington Management Group LLP increased its stake in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Natera by 3.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock valued at $315,194,000 after buying an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock valued at $265,747,000 after purchasing an additional 143,825 shares during the period. Maverick Capital Ltd. boosted its holdings in shares of Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock valued at $170,119,000 after purchasing an additional 269,706 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Natera by 25.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock worth $156,092,000 after buying an additional 246,246 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ:NTRA traded down $2.32 during trading on Friday, reaching $172.82. 857,965 shares of the company's stock traded hands, compared to its average volume of 1,326,767. Natera, Inc. has a fifty-two week low of $67.33 and a fifty-two week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $22.82 billion, a PE ratio of -98.19 and a beta of 1.66. The company has a 50-day simple moving average of $167.66 and a 200-day simple moving average of $140.49.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. During the same period last year, the firm earned ($0.95) EPS. The company's quarterly revenue was up 63.9% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In related news, insider John Fesko sold 663 shares of the firm's stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the completion of the transaction, the chief financial officer now directly owns 70,629 shares in the company, valued at $12,492,857.52. This represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 312,394 shares of company stock worth $52,333,520 in the last ninety days. Company insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NTRA shares. Sanford C. Bernstein increased their price objective on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. Robert W. Baird increased their price objective on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. The Goldman Sachs Group increased their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Canaccord Genuity Group increased their price objective on Natera from $165.00 to $180.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Finally, Guggenheim increased their price objective on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.